UNSPSC 51332004: Sertindole

This classification denotes a serotonin antagonist and dopamine antagonist with the molecular formula C24H26ClFN4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GVV4Z879SP, chemically known as 2-imidazolidinone, 1-(2-(4-(5-chloro-1-(4-fluorophenyl)-1h-indol-3-yl)-1-piperidinyl)ethyl)- but generally known as sertindole, which bears US NIH Compound Identifier 60149. European Medicines Agency schedules Sertindole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10498MIG.

UNSPSC 51332004 Sertindole is a Commodity code that nominally refers to a specific antipsychotic pharmaceutical, but recent state and local procurement activity under this code does not reflect targeted sourcing of sertindole itself. Instead, the opportunities posted show state and local health agencies and cooperative purchasing alliances procuring a broader range of pharmaceuticals, over-the-counter products, and drug-related health supplies. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances serving state and local governments (Minnesota MMCAP). The work being solicited spans naloxone and drug deactivation systems for opioid overdose response, direct-to-manufacturer prescription fulfillment programs, and generic multi-source pharmaceutical and OTC product contracts distributed through established wholesaler channels. Scope involves manufacturer pricing submissions, product identification by NDC code and SKU, compliance with FDA and Drug Supply Chain Security Act requirements, insurance and liability coverage, and administrative fee structures.

Activity concentrates in the South and Upper Midwest. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026 (due July 26, 2023, a date inconsistency in the source), seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building. Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to gauge vendor capability for direct-to-manufacturer prescription programs outside traditional PBM and GPO arrangements. Minnesota MMCAP, administered by the Minnesota Department of Administration and serving participating states including Oregon, released RFP S1070000015802 on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with awards effective July 1, 2026 and a two-year initial term. The MMCAP procurement weights price competitiveness at 75 percent of evaluation and imposes a 3 percent administrative fee on all purchases, with performance penalties of $200 to $1,500 per violation.